A series of cardiometabolic-related news items has been observed from Novo Nordisk, BI, Mineralys Therapeutics, and Insulet. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Lilly, Novo Nordisk, Senseonics, Esperion, and Fractyl Health. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items have been observed from Tandem Diabetes Care, Altimmune, Zevra Therapeutics, TIXiMED, MannKind, Silence Therapeutics, and Viatris. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items have been observed from Novo Nordisk, Viking Therapeutics/Pfizer, and Insulet. Below, FENIX provides highlights and insights for the respective news items.
Tandem initiated a trial evaluating the Tandem Freedom algorithm with its t:slim X2 pump in adults with T1DM (view CT.gov record). Existing Control-IQ technology users will use Control-IQ technology at home for a one-week run-in, then will use Tandem Freedom in a supervised hotel setting. For context, Tandem previously initiated the first feasibility trial for its Freedom algorithm in May 2024 (view CT.gov record). Below, FENIX provides highlights and insights into the trial.
A series of cardiometabolic-related news items have been observed from Medtronic, Sanofi, Allurion Technologies, and Viking Therapeutics. Below, FENIX provides highlights and insights for the respective news items.
Dexcom hosted its Q4 ‘24 earnings call (press release; slides) and provided updates across its business. Importantly, the company provided additional details into its next-gen G8 sensor platform. Below, FENIX provides highlights and insights from the call.
A series of cardiometabolic-related news items have been observed by Novartis, Metsera, Beta Bionics, Biocon, and Fractyl Health. Below, FENIX provides highlights and insights for the respective news items.
Beta Bionics filed a prospectus with the SEC outlining its goal of bringing in $114.4M in an IPO (view SEC filing). For context, earlier in January 2025, Beta Bionics filed a registration statement with the SEC relating to a proposed IPO to list its common stock on Nasdaq under the “BBNX” ticker (view SEC filing). Below, FENIX provides insight into the implications of Beta Bionics’s decision.
On the third day of JPM 2025, FENIX has provided coverage of presentations by major CVRM companies, including Insulet, Madrigal, Biomea Fusion, Ionis, and Sana Biotechnology. Separately, a series of CVRM-related news items has been observed: